Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30(+) Peripheral T-Cell Lymphomas: Results of a Phase I Study

PURPOSE: Front-line treatment of peripheral T-cell lymphomas (PTCL) involves regimens such as cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and results in a 5-year overall survival (OS) rate of less than 50%. This phase I open-label study evaluated the safety and activity of brentuxi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Fanale, Michelle A., Horwitz, Steven M., Forero-Torres, Andres, Bartlett, Nancy L., Advani, Ranjana H., Pro, Barbara, Chen, Robert W., Davies, Andrew, Illidge, Tim, Huebner, Dirk, Kennedy, Dana A., Shustov, Andrei R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2014
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4171358/
https://ncbi.nlm.nih.gov/pubmed/25135998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.54.2456
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados